Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients

Kılıç, Hatice; Argüder, Emine; Karalezli, Ayşegül; Ünsal, Ebru; Güner, Rahmet; Kayaslan, Bircan; Hasanoğlu, İmran; Ateş, İhsan; Civak, Musa; Akpınar, Esmehan; Parlak, Ebru; Sadi, Filiz; Kocaman, Yasin; Günay, Si̇bel; Metan, Esra; Er, Mükremin; Dalkıran, Aynil; Hezer, Habibe; Ergüden, Hülya; Hancıoğlu, Zeynep; Kalem, Ayşe Kaya; Eser, Fatma; Aypak, Adalet; Akıncı, Esragül; Karahmetoğlu, Selma; Gemcioğlu, Emin; Kalkan, Emra Asfuroglu; İnan, Osman; Yilmaz, Abdulrezzak; Güler, Bagdagul; Çopuroğlu, Esra; Turan, İşıl Özkoçak; Gökmen, Derya; Hayme, Serhat; Surel, Aziz Ahmet

doi:10.3389/fmed.2022.957598

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The degree to which these deaths could be prevented is related to various factors, including distinct prevention strategies, varying risk factors, and the availability of effective interventions, all of which vary by cause. Not all premature deaths are equally preventable among the leading causes or even within each specific leading cause category, as exemplified by certain types of cancer ( 40 ).…”

Section: Discussionmentioning

confidence: 99%

Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010–2022

García,

Rossen,

Matthews

et al. 2024

MMWR Surveill. Summ.

View full text Add to dashboard Cite

Problem/Condition A 2019 report quantified the higher percentage of potentially excess (preventable) deaths in U.S. nonmetropolitan areas compared with metropolitan areas during 2010–2017. In that report, CDC compared national, regional, and state estimates of preventable premature deaths from the five leading causes of death in nonmetropolitan and metropolitan counties during 2010–2017. This report provides estimates of preventable premature deaths for additional years (2010–2022). Period Covered 2010–2022. Description of System Mortality data for U.S. residents from the National Vital Statistics System were used to calculate preventable premature deaths from the five leading causes of death among persons aged <80 years. CDC’s National Center for Health Statistics urban-rural classification scheme for counties was used to categorize the deaths according to the urban-rural county classification level of the decedent’s county of residence (1: large central metropolitan [most urban], 2: large fringe metropolitan, 3: medium metropolitan, 4: small metropolitan, 5: micropolitan, and 6: noncore [most rural]). Preventable premature deaths were defined as deaths among persons aged <80 years that exceeded the number expected if the death rates for each cause in all states were equivalent to those in the benchmark states (i.e., the three states with the lowest rates). Preventable premature deaths were calculated separately for the six urban-rural county categories nationally, the 10 U.S. Department of Health and Human Services public health regions, and the 50 states and the District of Columbia. Results During 2010–2022, the percentage of preventable premature deaths among persons aged <80 years in the United States increased for unintentional injury (e.g., unintentional poisoning including drug overdose, unintentional motor vehicle traffic crash, unintentional drowning, and unintentional fall) and stroke, decreased for cancer and chronic lower respiratory disease (CLRD), and remained stable for heart disease. The percentages of preventable premature deaths from the five leading causes of death were higher in rural counties in all years during 2010–2022. When assessed by the six urban-rural county classifications, percentages of preventable premature deaths in the most rural counties (noncore) were consistently higher than in the most urban counties (large central metropolitan and fringe metropolitan) for the five leading causes of death during the study period. During 2010–2022, preventable premature deaths from heart disease increased most in noncore (+9.5%) and micropolitan counties (+9.1%) and decreased most in large central metropolitan counties (−10.2%). Preventable premature deaths from cancer decreased in all county categories, with the largest decreases in large central metropolitan and large fringe metropolitan counties (−100.0%; benchmark achieved in both county categories in 2019). In all count...

show abstract

Section: Discussionmentioning

confidence: 99%

Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010–2022

García,

Rossen,

Matthews

et al. 2024

MMWR Surveill. Summ.

View full text Add to dashboard Cite

show abstract

“…This is consistent with the reports of the WHO and other cohort studies, such as the WHO COVID-19 report of the People's Republic of China, which indicated that recorded deaths were generally people with advanced age or comorbid conditions, including chronic lung diseases [30]. In a prospective cohort study conducted among COVID-19 patients with chronic lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), lung cancer and interstitial lung diseases (ILDs) and those without chronic lung diseases, it was determined that patients with chronic lung disease had a 25.76% higher mortality risk [31]. To reduce the risk of death among these patients, health workers must consider the underlying COPD when treating COVID-19 in COPD patients.…”

Section: Discussionmentioning

confidence: 99%

Predictors of in-hospital mortality of patients with COVID-19 infection in a major treatment facility in Ghana.

OLIVER-COMMEY,

OWOO,

GHARTEY

et al. 2023

HSI Journal

View full text Add to dashboard Cite

Background: An estimated 17 –18% of hospitalisedCOVID-19 patients die. This has been attributed to varying symptomatic, prophylactic, patient management and health care factors. However, these factors have been shown to vary with population and setting dynamics. There is limited literature on the impact of these factors on COVID-19 mortality in the Ghanaian setting. This study, therefore, assessed the factors associated with mortality among COVID-19 hospitalised patients. Objective: The study aimed to assess the clinical and health-related factors associated with the mortality of COVID-19 patients admitted to a major treatment facility in Ghana. Methods: We conducted a retrospective study at Ghana Infectious Disease Center, involving a review of data collected on patients admitted to the facility from January 2021 to December 2021. Using a data abstraction tool on Kobo Collect, data on patient sociodemographic characteristics, clinical presentation, underlying conditions and vaccination status were extracted from patient folders and other inpatient registers. We analysed the data and estimated Odds ratios and their respective 95%CI intervals. Results: Out of the 271 patients admitted to the hospital within the study period, 8.86% (95%CI: 5.76–12.89) died. Being diabetic (aOR = 2.62, 95%CI: 1.08-6.35), having a cardiovascular-related disease (aOR = 4.06, 95%CI: 1.03–15.91), having a kidney disease (aOR = 4.56, 95%CI: 1.40-14.92), a chronic lung disease (aOR = 4.42, 95%CI: 1.45-13.53), and longer duration of admission (aOR = 1.06, 95%CI: 1.01-1.11) were associated with increased odds of death among the patients. Being vaccinated (aOR = 0.40, 95%CI: 0.11-0.49) was associated with a reduction in the odds of death among the patients. Conclusion: This study revealed a less than 10% mortality rate among the patients. Being unvaccinated, having an underlying condition (diabetes, cardiovascular-related diseases, chronic lung diseases and kidney disease) and having a longer duration of admission in the hospital were associated with increased risk of death among the patients.

show abstract

“…During the Coronavirus disease-2019 (COVID-19) pandemic, patients with chronic lung diseases such as Chronic Obstructive Pulmonary Disease, interstitial lung disease, and bronchiectasis were more affected than the healthy population. [1][2][3][4] Although the COVID-19 pandemic has lost its severity, SARS-CoV-2 viral infection seems to occur in our lives from now on, similar to other respiratory tract viral infections.…”

Section: Introductıonmentioning

confidence: 99%

Treatment adherence and anxiety levels of bronchiectasis patients in the COVID-19 pandemic

et al. 2023

View full text Add to dashboard Cite

It has been reported that during the coronavirus disease-2019 (COVID-19) pandemic, bronchiectasis patients were adversely affected due to their limited respiratory functions and acute exacerbations which were triggered by viral infections. The increased concern in the population during the pandemic has affected the attitudes of people toward avoiding disease and patients’ treatment compliance. It is unclear whether treatment adherence and anxiety levels of bronchiectasis patients have changed during the pandemic. We aimed to evaluate treatment adherence and anxiety levels in patients with bronchiectasis. A cross-sectional survey was conducted between May and November 2021. A total of 123 patients with bronchiectasis and 110 adults without chronic diseases were included in the control group. Patient demographic information, bronchiectasis follow-up data, and COVID-19 history were recorded. Then, patients filled out “MARS-5 Index” (Medical Adherence Report Scale-5), Beck Anxiety Scale and the Effect of Events Scale (IES-R). Responses of questionnaires were statistically analyzed. Our results showed that the majority of patients with bronchiectasis had high Medical Adherence Report Scale-5 index total scores during the COVID-19 pandemic (86.2%). The total scores on the Beck Anxiety Scale of bronchiectasis patients who did not have COVID-19 were significantly higher than those who had COVID-19 ( P = .04). The total scores on the IES-R were found to be significantly higher in the control group ( P < .001). No significant difference was found in the total scores on the Beck Anxiety Scale between the patients and the control group. The bronchiectasis patients had high adherence to their current treatment during the COVID-19 period and were less affected by the pandemic and its psychological effects compared to the healthy population. Furthermore, individuals diagnosed with bronchiectasis who were not infected with COVID-19 demonstrated increased levels of anxiety compared to those who were infected with COVID-19 which may be due to their concern about contracting the disease.

show abstract

Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients

Cited by 3 publications

References 29 publications

Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010–2022

Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010–2022

Predictors of in-hospital mortality of patients with COVID-19 infection in a major treatment facility in Ghana.

Treatment adherence and anxiety levels of bronchiectasis patients in the COVID-19 pandemic

Contact Info

Product

Resources

About